Indicazioni alla chimonucleolisi

Salvi, Valeria Franco

doi:10.1177/19714009890020s115

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the identification of imaging-based ADHD biological subtypes (biotypes) that may exhibit greater sensitivity to specific drug therapies holds promise for guiding a more personalized treatment approach with enhanced effectiveness. Meanwhile, multiple functional magnetic resonance imaging (fMRI) analyses have been performed to study ADHD subtype [6][7][8][9] , though in a relatively highly piecemeal way, which most relied heavily on prior clinical subtype divisions based on pure symptoms 3 and highlighted group-level differences via univariate statistic methods [10][11][12] . For example, ADHD-C were found to have hyper-connectivity in the pre-default mode network and lower network modularity compared to health controls (HC), whereas no such differences were found in the ADHD-I subtype 13 , whilst ADHD-C/HI to ADHD-I were often compared on the level of comorbidity, treatment response, and possible etiological factors 14 .…”

Section: Introductionmentioning

confidence: 99%

Functional Imaging Derived ADHD Biotypes Based on Deep Clustering May Guide Personalized Medication Therapy

Sui,

Feng,

Feng

et al. 2023

Preprint

View full text Add to dashboard Cite

Attention deficit hyperactivity disorder (ADHD) is one prevalent neurodevelopmental disorder with childhood onset, however, there is no clear correspondence established between clinical ADHD subtypes and primary medications. Identifying objective and reliable neuroimaging markers for categorizing ADHD biotypes may lead to more individualized, biotype-guided treatment. Here we proposed graph convolutional network plus deep clustering for ADHD biotype detection using functional network connectivity (FNC), resulting in two biotypes based on 1069 ADHD patients selected from Adolescent Brain and Cognitive Development (ABCD) study, which were well replicated on independent ADHD adolescents undergoing longitudinal medication treatment (n=130). Interestingly, in addition to differences in cognitive performance and hyperactivity/impulsivity symptoms, biotype 1 treated with methylphenidate demonstrated significantly better recovery than biotype 2 treated with atomoxetine (p<0.05, FDR corrected). This imaging-driven, biotype-guided approach holds promise for facilitating personalized treatment of ADHD, exploring possible boundaries through innovative deep learning algorithms aimed at improving medication treatment effectiveness.

show abstract